An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extensi
Clinical Trial Grant
Administered By
Pediatrics, Rheumatology
Awarded By
Sanofi US
Start Date
December 8, 2017
End Date
June 30, 2020
Administered By
Pediatrics, Rheumatology
Awarded By
Sanofi US
Start Date
December 8, 2017
End Date
June 30, 2020